A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Liver metastases; Neuroendocrine tumours; Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Status changed from recruiting to discontinued due to Slow accrual.
    • 15 Jul 2014 Status changed from not yet recruiting to recruiting, as per Robert H. Lurie Comprehensive Cancer Center record.
    • 10 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top